-- The NEW Official Alizyme Thread! --

Alphorn, large pharmas of the type who could afford to partner AZM on Cetilistat will undoubtably already have adequate sales forces and channels in place imo. Without prejudice to this, Roche's Xenical has already opened the market for Cetilistat. In that context, Cetilistat will virtually sell itself, particularly on the Internet, where the thousands of companies offering online medication will have a vested interest in promoting it themselves, rather than at AZM's or a partners expense, as an improvement on the existing best seller Xenical imo. Elsewhere, obesity clinicians who keep tabs on the development of the more important drugs like Cetilistat, will probably find out about it for themselves if they do not already know, will probably prefer it to appetite suppressents, will be aware of the improvements in comparison with Xenical, and may make the change-over to Cetilistat with little or no marketing push.